What is HC Wainwright’s Estimate for BNTC Q2 Earnings?

Benitec Biopharma Inc. (NASDAQ:BNTC) – HC Wainwright issued their Q2 2025 EPS estimates for Benitec Biopharma in a research report issued on Monday, December 16th. HC Wainwright analyst R. Selvaraju anticipates that the biotechnology company will earn ($0.27) per share for the quarter. HC Wainwright has a “Buy” rating and a $28.00 price target on the stock. The consensus estimate for Benitec Biopharma’s current full-year earnings is ($4.33) per share. HC Wainwright also issued estimates for Benitec Biopharma’s Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.34) EPS and FY2025 earnings at ($1.32) EPS.

Several other equities analysts also recently commented on BNTC. Baird R W upgraded Benitec Biopharma to a “strong-buy” rating in a research note on Thursday, December 12th. Guggenheim restated a “buy” rating and issued a $17.00 target price on shares of Benitec Biopharma in a research note on Tuesday, December 3rd. JMP Securities increased their price target on Benitec Biopharma from $16.00 to $18.00 and gave the stock a “market outperform” rating in a research note on Monday, October 14th. Piper Sandler reissued an “overweight” rating on shares of Benitec Biopharma in a report on Friday, October 18th. Finally, Oppenheimer assumed coverage on shares of Benitec Biopharma in a report on Wednesday, October 16th. They set an “outperform” rating and a $35.00 price objective on the stock. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $24.43.

Benitec Biopharma Stock Performance

BNTC traded down $0.03 during midday trading on Thursday, reaching $11.81. The company had a trading volume of 2,351 shares, compared to its average volume of 46,136. Benitec Biopharma has a 12-month low of $2.69 and a 12-month high of $13.29. The business has a 50-day moving average price of $10.73 and a two-hundred day moving average price of $9.38. The stock has a market cap of $274.18 million, a PE ratio of -4.16 and a beta of 0.88.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in BNTC. GAMMA Investing LLC boosted its stake in Benitec Biopharma by 20.3% during the third quarter. GAMMA Investing LLC now owns 6,540 shares of the biotechnology company’s stock valued at $60,000 after buying an additional 1,102 shares during the period. Geode Capital Management LLC raised its holdings in shares of Benitec Biopharma by 31.3% in the 3rd quarter. Geode Capital Management LLC now owns 83,987 shares of the biotechnology company’s stock valued at $772,000 after acquiring an additional 20,012 shares in the last quarter. Acuta Capital Partners LLC bought a new stake in shares of Benitec Biopharma during the 3rd quarter valued at about $274,000. Simplify Asset Management Inc. purchased a new position in shares of Benitec Biopharma during the second quarter worth about $358,000. Finally, Nantahala Capital Management LLC bought a new position in shares of Benitec Biopharma in the second quarter worth approximately $5,881,000. 52.19% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Suvretta Capital Management, L bought 42,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were acquired at an average price of $9.60 per share, with a total value of $403,200.00. Following the acquisition, the director now owns 7,957,365 shares of the company’s stock, valued at approximately $76,390,704. The trade was a 0.53 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 1.30% of the stock is owned by corporate insiders.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.